ArticleiScience2025
Recombination between fragile regions associated with chromosomal rearrangements in glioblastoma can be mediated by RAGs.
Article in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The RAGs, comprising RAG1 and RAG2, catalyze V(D)J recombination by recognizing recombination-signal sequences (RSS). Glioblastoma, the aggressive brain cancer, has many oncogenic chromosomal alterations; however, the mechanism of their generation is largely unknown. Here, we report that RAGs are expressed in human glioblastoma cells at transcript and protein levels. RNA-seq data analysis confirmed the expression of RAGs in the majority of patients with glioma. Analysis of patient breakpoint sequences reveals cryptic RSS in regions undergoing rearrangements. Biochemical studies demonstrate that RAGs can bind and cleave cryptic RSS in fragile regions (AMY1B, CAMK2D, RN7SKP123-MTF2, DIPK1A, IRX5-IRX6), albeit at lower efficiency. Recombination assay using episomes harboring the fragile regions showed aberrant recombination in these regions, and the efficiency was significantly reduced in RAG1 ablated cells. Finally, we recapitulate the glioblastoma associated AMY1B and RN7SKP123-MTF2 chromosomal rearrangement using an extrachromosomal assay. Thus, the present study provides mechanistic insights into the generation of chromosomal aberrations associated with glioblastoma.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.